Back to Search Results
Image Place holder

Evan Wuthrick, MD

★★★★★
★★★★★
4.8 (161 ratings)
Specialty: Radiation Oncology
Program: Radiation Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Anal Cancer, Basal Cell Carcinoma, Colon Cancer, Esophageal Cancer, Liver Cancer, Merkel Cell Carcinoma, Pancreatic Cancer, Rectal Cancer, Squamous Cell Carcinoma, Stomach (Gastric) Cancer

Dr. Wuthrick specializes in radiation therapy for skin cancers such as melanoma, Merkel cell carcinoma, squamous cell carcinoma, and basal cell carcinoma. He is also clinically interested in gastrointestinal cancers, including esophagealstomach andliver cancers, and cancers of the pancreas, colon, rectum and anus. Dr. Wuthrick is interested in the combination of high dose per fraction radiation therapy and immunotherapy in melanoma and Merkel cell carcinoma. He is involved in numerous early phase clinical trials exploring the role of MAPK pathway inhibitors with radiation therapy. Dr. Wuthrick has a leadership role in the NCI-sponsored cooperative groups NRG, Alliance for Oncology, and SWOG, which conduct large practice-changing clinical trials in cutaneous and gastrointestinal cancers.


Education & Training

Residency:

  • Washington University - Gynecologic Brachytherapy and Liquid Isotopes
  • St. Jude Children's Research Hospital - Pediatric Radiation Oncology
  • Thomas Jefferson University Hospital - Radiation Oncology

Medical School:

  • Jefferson Medical College - MD
Participating Trials

CLINICAL TRIAL 21965
A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART
Condition: Cutaneous
Intervention:
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022 Sep.400(10357):1008-1019. Pubmedid: 36108657. Pmcid: PMC9533323.
  • Sondak VK, Neves RI, Wuthrick EJ, Messina JL, Khushalani NI. Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma. Cancer. 2022 Nov.128(21):3764-3771. Pubmedid: 36066835.
  • Palmer JD, Prasad RN, Fabian D, Wei L, Yildiz VO, Tan Y, Grecula J, Welliver M, Williams T, Elder JB, Raval R, Blakaj D, Haglund K, Bazan J, Kendra K, Arnett A, Beyer S, Liebner D, Giglio P, Puduvalli V, Chakravarti A, Wuthrick E. Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. Radiother Oncol. 2022 May.170:21-26. Pubmedid: 35367525.
  • Linkowski LC, Sim AJ, Redler G, Brohl AS, Rosenberg SA, Wuthrick EJ. Delivery of Online Adaptive MRI-Guided Radiation Therapy for a Deaf Patient. Cureus. 2022 Aug.14(8):e27558. Pubmedid: 36059359. Pmcid: PMC9429821.
  • Wolfe AR, Chablani P, Siedow MR, Miller ED, Walston S, Kendra KL, Wuthrick E, Williams TM. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma. Radiat Oncol. 2021 Sep.16(1):181. Pubmedid: 34537078. Pmcid: PMC8449455.
  • Yaney AC, Rossfeld KK, Wu TC, Agnese DM, Terando AM, Wuthrick EJ, Howard JH. Adjuvant Radiation Does Not Affect Locoregional Control Following Resection of Melanoma Satellitosis or In-Transit Disease. Am Surg. 2021 Oct. Pubmedid: 34645291.
  • Glide-Hurst CK, Lee P, Yock AD, Olsen JR, Cao M, Siddiqui F, Parker W, Doemer A, Rong Y, Kishan AU, Benedict SH, Li XA, Erickson BA, Sohn JW, Xiao Y, Wuthrick E. Adaptive Radiation Therapy (ART) Strategies and Technical Considerations: A State of the ART Review From NRG Oncology. Int J Radiat Oncol Biol Phys. 2021 Mar.109(4):1054-1075. Pubmedid: 33470210. Pmcid: PMC8290862.
  • Straker RJ, Song Y, Sun J, Shannon AB, Cohen LS, Muradova E, Daou H, Krause K, Li S, Frederick DT, Rhodin KE, Brizel DM, Boland GM, Beasley GM, Wuthrick EJ, Sondak VK, Zager JS, Lin A, Lukens JN, Karakousis GC. Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul.28(7):3512-3521. Pubmedid: 33230747.
  • Koo J, Nardella L, Degnan M, Andreozzi J, Yu HM, Penagaricano J, Johnstone PAS, Oliver D, Ahmed K, Rosenberg SA, Wuthrick E, Diaz R, Feygelman V, Latifi K, Moros EG, Redler G. Triggered kV Imaging During Spine SBRT for Intrafraction Motion Management. Technol Cancer Res Treat. 2021 Jan.20. Pubmedid: 34855577. Pmcid: PMC8649431.
  • Patel AK, Pan X, Vila DM, Frankel WL, Chen W, Perry KA, Merritt RE, D'Souza DM, Wuthrick EJ, Williams TM. Perineural invasion predicts for locoregional failure in patients with oesophageal adenocarcinoma treated with neoadjuvant chemoradiotherapy. J Clin Pathol. 2021 Apr.74(4):228-233. Pubmedid: 32317290.
  • Swetter SM, Thompson JA, Albertini MR, Barker CA, Baumgartner J, Boland G, Chmielowski B, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossmann K, Guild S, Holder A, Johnson D, Joseph RW, Karakousis G, Kendra K, Lange JR, Lanning R, Margolin K, Olszanski AJ, Ott PA, Ross MI, Salama AK, Sharma R, Skitzki J, Sosman J, Wuthrick E, McMillian NR, Engh AM. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Ne. 2021 Apr.19(4):364-376. Pubmedid: 33845460.
  • Sim AJ, Frakes JM, Hoffe SE, Wuthrick E, Dilling TJ, Rosenberg S. Novel MR-Guided Radiotherapy Elective Rotation for Radiation Oncology Trainees. Cureus. 2020 Sep.12(9):e10706. Pubmedid: 33133871. Pmcid: PMC7594659.
  • Sim AJ, Palm RF, DeLozier KB, Feygelman V, Latifi K, Redler G, Washington IR, Wuthrick EJ, Rosenberg SA. MR-guided stereotactic body radiation therapy for intracardiac and pericardial metastases. Clin Transl Radiat Oncol. 2020 Nov.25:102-106. Pubmedid: 33204858. Pmcid: PMC7653008.
  • Farley CR, Perez MC, Soelling SJ, Delman KA, Harit A, Wuthrick EJ, Messina JL, Sondak VK, Zager JS, Lowe MC. Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?. Ann Surg Oncol. 2020 Jun.27(6):1978-1985. Pubmedid: 32103415.
  • Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, Bekaii-Saab T, Wuthrick E. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res. 2020 Jul.26(13):3117-3125. Pubmedid: 32253228. Pmcid: PMC7334091.
  • Rao PK, Barker C, Coit DG, Joseph RW, Materin M, Rengan R, Sosman J, Thompson JA, Albertini MR, Boland G, Carson Iii WE, Contreras C, Daniels GA, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossman K, Guild V, Johnson D, Karakousis G, Lange JR, Margolin K, Nath S, Olszanski AJ, Ott PA, Ross MI, Salama AK, Skitzki J, Swetter SM, Wuthrick E, McMillian NR, Engh A. NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. J Natl Compr Canc Ne. 2020 Feb.18(2):120-131. Pubmedid: 32023525.
  • Farley CR, Perez MC, Soelling SJ, Delman KA, Harit A, Wuthrick EJ, Messina JL, Sondak VK, Zager JS, Lowe MC. Correction to: Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?. Ann Surg Oncol. 2020 Dec.27(Suppl 3):983. Pubmedid: 32699930.
  • Fabian D, Ayan A, DiCostanzo D, Barney CL, Aljabban J, Diaz DA, Miller ED, Wuthrick E, Williams TM, Bazan JG. Increasing Radiation Dose to the Thoracic Marrow Is Associated With Acute Hematologic Toxicities in Patients Receiving Chemoradiation for Esophageal Cancer. Front Oncol. 2019 Mar.9:147. Pubmedid: 30931257. Pmcid: PMC6429979.
  • Yang L, Wald P, Roychowdhury S, Noonan AM, Zuo L, Chuang CC, Reeser J, Wuthrick E, Schmidt C, Williams T. Significant and Durable Clinical Response to Sorafenib and Radiation Therapy for a Patient With Stage IV Hepatocellular Carcinoma and LRRK2 Mutation. JCO Precis Oncol. 2019 Mar.3. Pubmedid: 32914030. Pmcid: PMC7446478.
  • Perez MC, Oliver DE, Weitman ES, Boulware D, Messina JL, Torres-Roca J, Cruse CW, Gonzalez RJ, Sarnaik AA, Sondak VK, Wuthrick EJ, Harrison LB, Zager JS. Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?. Ann Surg Oncol. 2019 Feb.26(2):379-385. Pubmedid: 30311164. Pmcid: PMC7771265.
  • Wuthrick EJ, Chablani P. Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management. Semin Radiat Oncol. 2019 Apr.29(2):166-170. Pubmedid: 30827455.
  • Oliver DE, Mohammadi H, Figura N, Frakes JM, Yamoah K, Perez BA, Wuthrick EJ, Naghavi AO, Caudell JJ, Harrison LB, Torres-Roca JF, Ahmed KA. Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Semin Radiat Oncol. 2019 Apr.29(2):111-125. Pubmedid: 30827449.
  • Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2019 Apr.17(4):367-402. Pubmedid: 30959471.
  • Wuthrick EJ, Harrison LB. A Deep Dive into the Diagnosis and Management of Regional Lymph Node Metastases. Semin Radiat Oncol. 2019 04.29(2):91-92. Pubmedid: 30827457.
  • Perez MC, de Pinho FR, Holstein A, Oliver DE, Naqvi SMH, Kim Y, Messina JL, Burke E, Gonzalez RJ, Sarnaik AA, Cruse CW, Wuthrick EJ, Harrison LB, Sondak VK, Zager JS. Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?. Ann Surg Oncol. 2018 Oct.25(11):3334-3340. Pubmedid: 30073600. Pmcid: PMC7771268.
  • Ahn PH, Machtay M, Anne PR, Cognetti D, Keane WM, Wuthrick E, Dicker AP, Axelrod RS. Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer. Am J Clin Oncol. 2018 May.41(5):441-446. Pubmedid: 27391356.
  • Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Jul.16(7):874-901. Pubmedid: 30006429.
  • Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Jul.16(7):852-871. Pubmedid: 30006428.
  • Nguyen P, Wuthrick E, Chablani P, Robinson A, Simmons L, Wu C, Arnold M, Harzman AE, Husain S, Schmidt C, Abdel-Misih S, Bekaii-Saab T, Chakravarti A, Williams TM. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol. 2018 Feb.41(2):140-146. Pubmedid: 26535992. Pmcid: PMC4860166.
  • Makary MS, Krishner LS, Wuthrick EJ, Bloomston MP, Dowell JD. Yttrium-90 microsphere selective internal radiation therapy for liver metastases following systemic chemotherapy and surgical resection for metastatic adrenocortical carcinoma. World J Clin Oncol. 2018 Feb.9(1):20-25. Pubmedid: 29468134. Pmcid: PMC5807889.
  • Walston S, Salloum J, Grieco C, Wuthrick E, Diaz DA, Barney C, Manilchuk A, Schmidt C, Dillhoff M, Pawlik TM, Williams TM. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation. Am J Clin Oncol. 2018 Dec.41(12):1185-1192. Pubmedid: 29727311. Pmcid: PMC6215749.
  • Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Ne. 2018 Apr.16(4):359-369. Pubmedid: 29632055.
  • Li P, Wuthrick E, Rappaport JA, Kraft C, Lin JE, Marszalowicz G, Snook AE, Zhan T, Hyslop TM, Waldman SA. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. Cancer Res. 2017 Sep.77(18):5095-5106. Pubmedid: 28916678. Pmcid: PMC5678756.
  • Williams NL, Wuthrick EJ, Kim H, Palmer JD, Garg S, Eldredge-Hindy H, Daskalakis C, Feeney KJ, Mastrangelo MJ, Kim LJ, Sato T, Kendra KL, Olencki T, Liebner DA, Farrell CJ, Evans JJ, Judy KD, Andrews DW, Dicker AP, Werner-Wasik M, Shi W. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2017 Sep.99(1):22-30. Pubmedid: 28816150.
  • Wald P, Liu XS, Pettit C, Dillhoff M, Manilchuk A, Schmidt C, Wuthrick E, Chen W, Williams TM. Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature. Oncotarget. 2017 Sep.8(42):73345-73361. Pubmedid: 29069873. Pmcid: PMC5641216.
  • Wright CL, Binzel K, Zhang J, Wuthrick EJ, Knopp MV. Clinical feasibility of Y digital PET/CT for imaging microsphere biodistribution following radioembolization. Eur J Nucl Med Mol Imaging. 2017 Jul.44(7):1194-1197. Pubmedid: 28405728.
  • Chablani P, Nguyen P, Pan X, Robinson A, Walston S, Wu C, Frankel WL, Chen W, Bekaii-Saab T, Chakravarti A, Wuthrick E, Williams TM. Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. Am J Clin Oncol. 2017 Dec.40(6):561-568. Pubmedid: 26703815. Pmcid: PMC5940000.
  • Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T. The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Dec.40(6):531-534. Pubmedid: 25723741. Pmcid: PMC4549218.
  • Wright CL, Zhang J, Binzel K, Wuthrick EJ, Knopp MV. 90Y Digital PET/CT Imaging Following Radioembolization. Clin Nucl Med. 2016 Dec.41(12):975-976. Pubmedid: 27749420.
  • Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, Le QT, Gillison ML. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015 Jan.33(2):156-164. Pubmedid: 25488965. Pmcid: PMC4279235.
  • Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015 Apr.22(4):1153-1159. Pubmedid: 25358667. Pmcid: PMC4373613.
  • Wuthrick EJ, Curran WJ, Camphausen K, Lin A, Glass J, Evans J, Andrews DW, Axelrod R, Shi W, Werner-Wasik M, Haacke EM, Hillman GG, Dicker AP. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma. Int J Radiat Oncol Biol Phys. 2014 Oct.90(2):369-375. Pubmedid: 25104067. Pmcid: PMC8374468.
  • Lawrence YR, Whiton MA, Symon Z, Wuthrick EJ, Doyle L, Harrison AS, Dicker AP. Quality assurance peer review chart rounds in 2011: a survey of academic institutions in the United States. Int J Radiat Oncol Biol Phys. 2012 Nov.84(3):590-595. Pubmedid: 22445006.
  • Evans J, Chen Q, Wuthrick E, Weldon M, Rong Y. SU-E-T-581: Planning Evaluation of Step-And-Shoot IMRT, RapidArc and Helical TomoTherapy for Hippocampal-Avoidance Whole Brain Radiotherapy (HA-WBRT). Med Phys. 2012 Jun.39(6Part19):3839. Pubmedid: 28517063.
  • Zaorsky NG, Malatesta TM, Den RB, Wuthrick E, Ahn PH, Werner-Wasik M, Shi W, Dicker AP, Anne PR, Bar-Ad V, Showalter TN. Assessing the value of an optional radiation oncology clinical rotation during the core clerkships in medical school. Int J Radiat Oncol Biol Phys. 2012 Jul.83(4):e465-e469. Pubmedid: 22704704.
  • Wuthrick EJ, Kamrava M, Curran WJ, Werner-Wasik M, Camphausen KA, Hyslop T, Axelrod R, Andrews DW, Glass J, Machtay M, Dicker AP. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer. 2011 Dec.117(24):5548-5559. Pubmedid: 21647871. Pmcid: PMC3170674.

Grants

Title: NRG Oncology Network Group Operations Center
Sponsor: Nat Institutes of Health
PI: Wuthrick, E.

Patient Comments
Overall Satisfaction
4.8
★★★★★
★★★★★

161 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments